Stereotaxis, Inc.

Equities

STXS

US85916J4094

Advanced Medical Equipment & Technology

Market Closed - Nyse 04:00:00 2024-04-26 pm EDT 5-day change 1st Jan Change
2.3 USD -2.13% Intraday chart for Stereotaxis, Inc. -7.63% +31.43%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Transcript : Stereotaxis, Inc., Q4 2023 Earnings Call, Mar 04, 2024
Earnings Flash (STXS) STEREOTAXIS Reports Q4 Revenue $4.6M, vs. Street Est of $7.7M MT
Stereotaxis, Inc. Announces Regulatory Submissions of the MAGiC Ablation Catheter in Europe and the United States CI
Stereotaxis, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023 CI
Stereotaxis, Inc. Provides Revenue Guidance for the First Quarter and Full Year 2024 CI
North American Morning Briefing : Stock Futures -2- DJ
Roth MKM Starts Coverage on Stereotaxis with Buy Rating, $5 Price Target MT
Stereotaxis Announces First Patients Successfully Treated Using Magic Ablation Catheter CI
B. Riley Trims Stereotaxis' PT to $4 From $4.50 After Slight Q3 Miss, Maintains Buy Rating MT
Transcript : Stereotaxis, Inc., Q3 2023 Earnings Call, Nov 09, 2023
Stereotaxis, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Earnings Flash (STXS) STEREOTAXIS Posts Q3 Revenue $7.8M, vs. Street Est of $8.3M MT
Stereotaxis Says First US Arrhythmia Patients Treated with Robotic Navigation and Abbott's Cardiac Mapping System MT
Stereotaxis Launches and Successfully Completes the First Procedures Using the Advanced Genesis Robotic Magnetic Navigation System CI
Transcript : Stereotaxis, Inc., Q2 2023 Earnings Call, Aug 10, 2023
Earnings Flash (STXS) STEREOTAXIS Reports Q2 Revenue $7.9M, vs. Street Est of $6.7M MT
Stereotaxis, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Stereotaxis, Inc. Reiterates Revenue Guidance for the Year 2023 CI
North American Morning Briefing : Attention Turns -2- DJ
Stereotaxis' Robotic Technology Combined With Abbott's Cardiac Mapping System Treats Arrhythmia Patients MT
B. Riley Adjusts Price Target on Stereotaxis to $4.50 From $5.50, Maintains Buy Rating MT
Stereotaxis to Initiate First-In-Human Trial to Support CE Mark Application of Magic Catheter CI
Stereotaxis Says First Arrhythmia Patients Treated With Genesis Robotic System at Chicago Hospital MT
Stereotaxis, Inc. Announces the First Treatment of Patients with Newly Launched Genesis Robotic Magnetic Navigation System At Advocate Christ Medical Center in Chicago, Illinois CI
Stereotaxis Files $100 Million Mixed Shelf MT
Chart Stereotaxis, Inc.
More charts
Stereotaxis, Inc. designs, manufactures, and markets robotic systems, instruments and information systems for the interventional laboratory. Its proprietary robotic technology, Robotic Magnetic Navigation, fundamentally transforms endovascular interventions using precise computer-controlled magnetic fields to directly control the tip of flexible interventional catheters or devices. The Company’s primary products include the Genesis RMN System, the Odyssey Solution, and other related devices. Through its strategic relationships with fluoroscopy system manufacturers, providers of catheters and electrophysiology mapping systems, and other parties, the Company offers its customers x-ray systems and other accessory devices. The Genesis RMN System is designed to enable physicians to complete more complex interventional procedures by providing image-guided delivery of catheters through the blood vessels and chambers of the heart to treatment sites.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
2.3 USD
Average target price
4.5 USD
Spread / Average Target
+95.65%
Consensus
  1. Stock Market
  2. Equities
  3. STXS Stock
  4. News Stereotaxis, Inc.
  5. Stereotaxis' Robotic Technology Combined With Abbott's Cardiac Mapping System Treats Arrhythmia Patients